Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | YAP1 | P46937 | 3/20 | 0.56 |
| ▸ | GLS | O94925 | 2/20 | 0.53 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7445355 | 0.83 | GLS (0.55) | YAP1GLSEPHX1HPGDGPR119 | |
| SCHEMBL38665800 | 0.83 | GLS (0.50) | YAP1GLSEPHX1HPGDGPR119 | |
| SCHEMBL21551314 | 0.82 | GLS (0.54) | YAP1GLSEPHX1HPGDGPR119 | |
| SCHEMBL19979258 | 0.81 | HPGD (0.49) | GLSEPHX1HPGDGPR119KDM4E | |
| SCHEMBL13930886 | 0.81 | EPHX1 (0.69) | YAP1GLSEPHX1HPGDKDM4E | |
| SCHEMBL5573225 | 0.81 | KDM4E (0.63) | GLSEPHX1HPGDGPR119KDM4E | |
| SCHEMBL13059914 | 0.80 | KDM4E (0.56) | GLSEPHX1HPGDGPR119KDM4E | |
| SCHEMBL23674877 | 0.80 | HPGD (0.61) | EPHX1HPGDNPC1ALDH1A1MAPT | |
| SCHEMBL106242 | 0.80 | KDM4E (0.52) | YAP1GLSEPHX1HPGDGPR119 | |
| SCHEMBL6608848 | 0.79 | HPGD (0.53) | GLSEPHX1HPGDGPR119KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026107377-A1 | PHARMACOLOGICAL RE-ACTIVATION OF MUTANT PVHL | KARANICOLAS JOHN (US) | 2026-05-21 | — | — | WO | disclosed |
| US-8003662-B2 | Heterobicyclic thiophene compounds and methods of use | ARRAY BIOPHARMA, INC. (US) | 2011-08-23 | — | — | US | disclosed |
| US-7115597-B2 | Tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2006-10-03 | — | — | US | disclosed |
| US-20040063720-A1 | Tyrosine kinase inhibitors | MERCK & CO., INC. | 2004-04-01 | — | — | US | disclosed |
| EP-1341540-A2 | TYROSINE KINASE INHIBITORS | Merck & Co., Inc. (US) | 2003-09-10 | — | — | EP | disclosed |
| US-20020137755-A1 | Tyrosine kinase inhibitors | BILODEAU MARK T (US) | 2002-09-26 | — | — | US | disclosed |
| WO-2002045652-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2002-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137755-A1 | Tyrosine kinase inhibitors | ERBB2, TYRO3, TIE1 | YAP1 1162/4885GLS 1053/4885EPHX1 2048/4885 |
| US-20040063720-A1 | Tyrosine kinase inhibitors | ERBB2, TYRO3, TIE1 | YAP1 1162/4885GLS 1053/4885EPHX1 2048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.